Literature DB >> 26077977

Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Touraj Farazmandfar1,2, Mohammad Reza Haghshenas2, Majid Shahbazi1,3.   

Abstract

Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic approaches. Nevertheless, problems such as the specific recognition of target cells and uncontrolled expression of the transgene can restrict their use in vivo. Herein we present a new HIV-inducible promoter to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a novel third-generation lentiviral vector system with more safety and a specific tropism to the target cells. The new promoter, CkRhsp, was constructed from the chicken β-actin core promoter with the R region of HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV-1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 envelope in structure of third-generation lentiviral vector. The new fusion promoter efficiently expressed shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable transduction assays. The new viral vector infected only CD4+cells. CkRhsp promoter may be safer than other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches in vivo.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077977      PMCID: PMC4630793          DOI: 10.1089/hum.2015.031

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  41 in total

1.  Breakthrough of the year. Small RNAs make big splash.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2002-12-20       Impact factor: 47.728

2.  Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.

Authors:  Hoshang J Unwalla; Hai-Tang Li; Ingrid Bahner; Ming-Jie Li; Donald Kohn; John J Rossi
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.

Authors:  Geetanjali Sachdeva; Jenice D'Costa; Jang E Cho; Kritika Kachapati; Vidita Choudhry; Suresh K Arya
Journal:  J Med Virol       Date:  2007-02       Impact factor: 2.327

4.  Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis.

Authors:  S Y Paik; A Banerjea; C J Chen; Z Ye; G G Harmison; M Schubert
Journal:  Hum Gene Ther       Date:  1997-06-10       Impact factor: 5.695

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

6.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells.

Authors:  Priscilla Y Yam; Shulian Li; Jerry Wu; Jun Hu; John A Zaia; Jiing-Kuan Yee
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

7.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

8.  Direct and indirect contributions of RNA secondary structure elements to the initiation of HIV-1 reverse transcription.

Authors:  Valerie Goldschmidt; Mickael Rigourd; Chantal Ehresmann; Stuart F J Le Grice; Bernard Ehresmann; Roland Marquet
Journal:  J Biol Chem       Date:  2002-08-22       Impact factor: 5.157

9.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Authors:  Ellen M Westerhout; Marcel Ooms; Monique Vink; Atze T Das; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

10.  A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.

Authors:  Olivier ter Brake; Ben Berkhout
Journal:  J RNAi Gene Silencing       Date:  2005-10-14
View more
  3 in total

1.  A novel screening system based on gene targeting to enrich the modified mammalian cells: without leaving selection marker and additional sequence.

Authors:  Abtin Behmardi; Majid Shahbazi; Masoud Golalipour; Touraj Farazmandfar
Journal:  3 Biotech       Date:  2019-09-05       Impact factor: 2.406

2.  A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition.

Authors:  Abtin Behmardi; Touraj Farazmandfar
Journal:  Drug Deliv Transl Res       Date:  2022-01-31       Impact factor: 5.671

3.  Investigating Effect of Rapamycin and Metformin on Angiogenesis in Hepatocellular Carcinoma Cell Line.

Authors:  Mandana Rastegar; Haji-Amin Marjani; Yaghoub Yazdani; Majid Shahbazi; Masoud Golalipour; Touraj Farazmandfar
Journal:  Adv Pharm Bull       Date:  2018-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.